Discovery and development of selective M3 antagonists for clinical use

Life Sciences

Volumn 60, Issue 13-14, 1997, Pages 1053-1060

  Alabaster, V A ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

M3 antagonists; muscarinic receptor subtypes; preclinical pharmacology

Indexed keywords

ACETYLCHOLINE; ATROPINE; AUTORECEPTOR; DARIFENACIN; IPRATROPIUM BROMIDE; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC M3 RECEPTOR ANTAGONIST; MUSCARINIC M4 RECEPTOR; MUSCARINIC M5 RECEPTOR; RADIOLIGAND; RECEPTOR SUBTYPE; REVATROPATE; UNCLASSIFIED DRUG;

BLADDER; CHOLINERGIC NERVE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DOG; DRUG SELECTIVITY; GUINEA PIG; HEART ATRIUM; HEART RATE; HUMAN; ILEUM; INTESTINE FUNCTION DISORDER; NONHUMAN; RABBIT; SUBMANDIBULAR GLAND; TRACHEA; URGE INCONTINENCE; VAS DEFERENS;

ANIMALS; BENZOFURANS; DOGS; GUINEA PIGS; HUMANS; LUNG DISEASES, OBSTRUCTIVE; MUSCARINIC ANTAGONISTS; PYRROLIDINES; QUINUCLIDINES; RABBITS; RECEPTOR, MUSCARINIC M3; RECEPTORS, MUSCARINIC;

EID: 0030902107     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(97)00047-7     Document Type: Conference Paper

References (24)

1. B. GANDEVA, Postgrad. Med. J. 51 (Suppl. 7) 13-20 (1975).
2. R.B. BARLOW, K.J. BERRY, P.A.M. GLENTON, N.M. NIKOLAN & K.S. SOH, Br. J. Pharmacol 58 613-620 (1976).
3. M.P. CAULFIELD, Pharmacol. Ther. 58 319-379 (1993).
4. N.J. GROSS and M.S. SKORODIN. Am. Rev. Respir. Dis. 129 856-870 (1984).
5. P.J. BARNES, Life Sci, 52 521-527 (1993).
6. I. WESSLER, D. HELLWIG and K. RACKE, Arch. Pharmacol. 342 387-393 (1990).
7. P.J. BARNES, P. MINETTE and J. MACLAGAN, Trends. Pharmacol. Sci, 9 412-416 (1988).
8. A.D. FRYER and J. MACLAGAN, Br. J. Pharmacol. 83 973-978 (1984).
9. H. KILBINGER, R.S. VON BARDELEBEN, H. SIEFKEN & D. WOLF, Life Sci. 56 981-987 (1995).
10. B. A. MOORE, R.F. KEIR, E.F. STUART, K.N. WRIGHT and A. STOBIE, Eur Resp J. 9 (Suppl. 23) 30S (1996).
11. R.F. KEIR, B.A. MOORE, V.A. ALABASTER, Br. J. Pharmacol. 102 337P (1991).
12. R.F. KEIR, E.F. STUART, K.N. WRIGHT and B.A. MOORE, Eur Resp. J. 9 (Suppl. 23) 29S (1996).
13. I. MACHIN, P.A. MERNER, L.M. OAKES, M.R. SUTTON, I.R. WITHERDEN, Eur. Resp. J. 9 (Suppl. 23) 29S (1996).
14. P.A.H. MINETTE, J. LAMMERS, C.M.S. DIXON, M.T. McCUSTER, & P.J. BARNES, J. Appl. Physiol 67 2461-2465 (1989).
15. A.D. FRYER and D.B. JACOBY, Life Sci. 52 529-536 (1993).
16. F.P.V. MAESEN, J.J. SMEETS, P. SMEETS, I. GORTER DE VRIES and M. HODGES, Eur Resp. J. 9 (Suppl. 23) 29S (1996).
17. C.M. SMITH and R.M. WALLIS, J. of Recep. and Signal Transd. Res. In press
18. R.M. WALLIS, R.A. BURGES, P.E. CROSS, A.R. MACKENZIE, D.T. NEWGREEN and P. QUINN, Pharmacol. Res. 31 P54 (1995).
19. D.T. NEWGREEN & A.M. NAYLOR, Br. J. Pharmacol. 117 107P (1996).
20. R.M. EGLEN, A.D. MICHEL, W.W. MONTGOMERY, E.A. KUNYSZ, C.A. MACHADO and R.L. WHITING, Br. J. Pharmacol. 99 637-642 (1990).
21. R.M. WALLIS, Life Sci. 56 861-868 (1995).
22. P. QUINN, P. MCINTYRE, W.D. MINER and R.M. WALLIS, Br. J. Pharmacol. 119 198P (1996).
23. D.T. NEWGREEN, C.W.P. ANDERSON, A.J. CARTER & A.M. NAYLOR, Neurourology and Urodyn. 14 555 (1995).
24. D.J. ROSARIO, B.R. LEAKER, D.J. SMITH and C.R. CHAPPLE, Neurourology and Urodyn. 14 5 (1995).